Terms: = Sarcomas AND MDM2, HDM2, 4193, ENSG00000135679, HDMX, MGC71221, hdm2, Q00987 AND Treatment
228 results:
1. Well-differentiated liposarcomas and dedifferentiated liposarcomas: Systemic treatment options for two sibling neoplasms.
Kyriazoglou A; Pagkali A; Kotsantis I; Economopoulou P; Kyrkasiadou M; Moutafi M; Gavrielatou N; Anastasiou M; Boulouta A; Pantazopoulos A; Giannakakou M; Digklia A; Psyrri A
Cancer Treat Rev; 2024 Apr; 125():102716. PubMed ID: 38492514
[TBL] [Abstract] [Full Text] [Related]
2. Association of mdm2 Overexpression in Ameloblastomas with
Tosios KI; Kalogirou EM; Koutlas IG
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396916
[TBL] [Abstract] [Full Text] [Related]
3. Factors predictive of second-line chemotherapy in soft tissue sarcoma: An analysis of the National Genomic Profiling Database.
Mochizuki T; Ikegami M; Akiyama T
Cancer Sci; 2024 Feb; 115(2):575-588. PubMed ID: 38115234
[TBL] [Abstract] [Full Text] [Related]
4. Pediatric parosteal osteosarcoma of the distal radius causing extensive erosive mass effect of the adjacent ulna: a case report.
Perloff A; Park S; Panganiban R; deVries J
BMC Musculoskelet Disord; 2023 Dec; 24(1):950. PubMed ID: 38057715
[TBL] [Abstract] [Full Text] [Related]
5. Detection of Novel Tyrosine Kinase Fusion Genes as Potential Therapeutic Targets in Bone and Soft Tissue sarcomas Using DNA/RNA-based Clinical Sequencing.
Hasegawa N; Hayashi T; Niizuma H; Kikuta K; Imanishi J; Endo M; Ikeuchi H; Sasa K; Sano K; Hirabayashi K; Takagi T; Ishijima M; Kato S; Kohsaka S; Saito T; Suehara Y
Clin Orthop Relat Res; 2024 Mar; 482(3):549-563. PubMed ID: 38014853
[TBL] [Abstract] [Full Text] [Related]
6. Biology and Management of Deep-seated Atypical Lipomatous Tumor of the Extremities.
Nishio J; Nakayama S; Chijiiwa Y; Aoki M
Anticancer Res; 2023 Oct; 43(10):4295-4301. PubMed ID: 37772567
[TBL] [Abstract] [Full Text] [Related]
7. Sarcoma care in the era of precision medicine.
Wallander K; Öfverholm I; Boye K; Tsagkozis P; Papakonstantinou A; Lin Y; Haglund de Flon F
J Intern Med; 2023 Dec; 294(6):690-707. PubMed ID: 37643281
[TBL] [Abstract] [Full Text] [Related]
8. The Landscape of Alterations from 1407 Ultra-Rare sarcomas from the AACR GENIE Database: Clinical Implications.
Denu RA; Moyers JT; Gouda MA; Conley AP; Lazar AJ; Subbiah V
Clin Cancer Res; 2023 Nov; 29(22):4669-4678. PubMed ID: 37643131
[TBL] [Abstract] [Full Text] [Related]
9. KDM2B-Rearranged Soft Tissue sarcomas Expand the Concept of BCOR-Associated Sarcoma.
Motoi T; Hirata M; Kukita Y; Satomi K; Tamura H; Adachi S; Matsushita Y; Horiguchi SI; Hishima T; Ikegami M; Okuma T; Tao K; Arakawa A; Ogawa C; Matsuda K; Ichimura K; Nakamura H; Mori T; Yoshida A
Mod Pathol; 2023 Nov; 36(11):100317. PubMed ID: 37634866
[TBL] [Abstract] [Full Text] [Related]
10. Epithelioid dedifferentiated liposarcoma: A clinicopathological and molecular study of 6 cases.
Tu Y; Zhu P; Lao IW; Yu L; Wang J
Ann Diagn Pathol; 2023 Dec; 67():152203. PubMed ID: 37634346
[TBL] [Abstract] [Full Text] [Related]
11. Deciphering the Signaling Mechanisms of Osteosarcoma Tumorigenesis.
Nirala BK; Yamamichi T; Yustein JT
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511127
[TBL] [Abstract] [Full Text] [Related]
12. Primary cardiac sarcomas: A clinicopathologic study in a single institution with 25 years of experience with an emphasis on mdm2 expression and adjuvant therapy for prognosis.
Cho H; Song IH; Jo U; Jeong JS; Koo HJ; Yang DH; Jung SH; Song JS; Cho KJ
Cancer Med; 2023 Aug; 12(16):16815-16828. PubMed ID: 37395142
[TBL] [Abstract] [Full Text] [Related]
13. Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an mdm2 Inhibitor, in Intimal Sarcoma with mdm2 Amplification: An Open-Label Phase Ib/II Study.
Koyama T; Shimizu T; Kojima Y; Sudo K; Okuma HS; Shimoi T; Ichikawa H; Kohsaka S; Sadachi R; Hirakawa A; Yoshida A; Ando RM; Ueno T; Yanagaki M; Matsui N; Nakamura K; Yamamoto N; Yonemori K
Cancer Discov; 2023 Aug; 13(8):1814-1825. PubMed ID: 37369013
[TBL] [Abstract] [Full Text] [Related]
14. treatment of De-Differentiated Liposarcoma in the Era of Immunotherapy.
Zhou MY; Bui NQ; Charville GW; Ganjoo KN; Pan M
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298520
[TBL] [Abstract] [Full Text] [Related]
15. The mdm2-p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced or Metastatic Solid Tumors: Results of a Phase Ia, First-in-Human, Dose-Escalation Study.
LoRusso P; Yamamoto N; Patel MR; Laurie SA; Bauer TM; Geng J; Davenport T; Teufel M; Li J; Lahmar M; Gounder MM
Cancer Discov; 2023 Aug; 13(8):1802-1813. PubMed ID: 37269344
[TBL] [Abstract] [Full Text] [Related]
16. New targeted treatments for advanced sarcomas.
Li CC; Chen TW
Curr Opin Oncol; 2023 Jul; 35(4):309-314. PubMed ID: 37222206
[TBL] [Abstract] [Full Text] [Related]
17. Proteasome Inhibition Sensitizes Liposarcoma to mdm2 Inhibition with Nutlin-3 by Activating the ATF4/CHOP Stress Response Pathway.
Ludwig MP; Galbraith MD; Eduthan NP; Hill AA; Clay MR; Tellez CM; Wilky BA; Elias A; Espinosa JM; Sullivan KD
Cancer Res; 2023 Aug; 83(15):2543-2556. PubMed ID: 37205634
[TBL] [Abstract] [Full Text] [Related]
18. MicroRNA-215-5p promotes proliferation, invasion, and inhibits apoptosis in liposarcoma cells by targeting mdm2.
Song Z; Bai J; Jiang R; Wu J; Yang W
Cancer Med; 2023 Jun; 12(12):13455-13470. PubMed ID: 37132262
[TBL] [Abstract] [Full Text] [Related]
19. [Clinical value of fluorescence
Wang W; Li X; Liu P; Dong Y
Beijing Da Xue Xue Bao Yi Xue Ban; 2023 Apr; 55(2):228-233. PubMed ID: 37042132
[TBL] [Abstract] [Full Text] [Related]
20. Brightline-1: phase II/III trial of the mdm2-p53 antagonist BI 907828 versus doxorubicin in patients with advanced DDLPS.
Schöffski P; Lahmar M; Lucarelli A; Maki RG
Future Oncol; 2023 Mar; 19(9):621-629. PubMed ID: 36987836
[TBL] [Abstract] [Full Text] [Related]
[Next]
